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Non-small cell lung cancers (NSCLC) with epidermal growth factor receptor 
(EGFR) gene mutations can exhibit a strong dependence on mutant EGFR signaling for 
growth and survival. They are also sensitive to EGFR tyrosine kinase inhibitors (TKIs), 
which provide superior clinical benefits to conventional chemotherapy.  However, despite 
initial response, most patients experience relapse with resistant tumors within a year. 
This study aims to identify modifiers of dependence on mutant EGFR signaling and the 
mechanisms by which they do so in order to improve therapeutic strategies and 
outcomes. 
A genome-scale CRISPR-Cas9 genetic knockout screen was conducted to 
identify genes whose loss-of-function confer EGFR-TKI resistance.  A pooled sgRNA 
library targeted more than 18,000 protein-coding human genes with multiple sgRNAs.  
The lung cancer cell line HCC827 was used as it is EGFR-mutant and sensitive to EGFR 
TKIs.  Cells were transduced with the sgRNA library and cultured in the presence of 
erlotinib, an EGFR TKI, or DMSO control for 17 days. sgRNAs that were enriched in 
erlotinib-treated groups over control groups were identified, indicating genes whose loss-
of-function confer TKI resistance. The RNAi gene enrichment ranking (RIGER) algorithm 
was applied to identify gene hits with enrichment of multiple sgRNAs. 
Top-ranked candidates include previously confirmed genes PTEN, NF1, NF2, 
TSC1, and TSC2; validating this system as a means to identify modifiers of EGFR 
dependence in HCC827 cells. A novel candidate gene is the E3 ubiquitin ligase HUWE1. 
I showed that suppression of HUWE1 by inducible short hairpin RNA (shRNA) in 
HCC827 cells re-activated AKT and ERK1/2 signaling pathways and increased cell 
survival in response to EGFR inhibition. These findings were confirmed in vivo by 
implanting mouse xenografts of HCC827 cells with suppressed HUWE1 expression and 
iv 
 
monitoring tumor development in response to erlotinib.  Tumors with suppressed 
HUWE1 continued to grow into large tumors whereas control cells had durable tumor 
regression throughout the treatment period.   
We have shown that dependence on EGFR signaling can be decreased in 
EGFR-mutant lung cancer cells through mechanisms that involve the activation of AKT 
and ERK1/2 signaling pathways.  Future studies involve identifying HUWE1 
substrates/interactions that participate in tumor cell response to EGFR inhibitors, 
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Introduction and Background 
 
Lung cancer statistics 
Lung cancer is the leading cause of cancer-related deaths in both men and 
women in the United States, accounting for 27% of cancer deaths in 2016 and an 
estimated 220,000 new cases [1].  The leading risk factor for lung cancer is cigarette 
smoking , accounting for 82% of lung cancer deaths in the United States [2] 
The overall 5-year survival rate is 17.4% and for those with stage IV disease at 
diagnosis, this rate drops to a dismal less than 2%.  Unfortunately, most patients are 
diagnosed with advanced-stage disease [3].  Unlike other cancer types, which have 
seen a combined 5-year relative survival rate increase of 20%, lung cancer survival rates 
have seen only marginal increases over the past four decades, as the 5-year survival 
rate was 12% in 1977 [1].  The advent of low-dose helical computed tomography, 
however, has resulted in earlier detection and may help to raise survival rates and 
reduce lung cancer mortality [4]. 
Lung cancer subtypes  
Lung cancers can be derived from neural crest cells, which develop into small-
cell lung cancer (SCLC), or epithelial cells, which develop into non-small cell lung 
cancers.  NSCLC can be further divided into adenocarcinoma, squamous cell 
carcinomas, large cell carcinomas, and sarcomatoid carcinomas.  Approximately 80% of 
lung cancers are NSCLC and approximately 60% of NSCLC are adenocarcinomas [1].  
The various lung cancer subtypes have resulted in a diversity of treatment strategies due 
to their intrinsically different sensitivities to distinct agents. 
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NSCLC treatment strategies 
Treatment decisions for NSCLC patients are based on histomorphological, 
immunohistochemical, and molecular characterizations.  Until recent advances in TKI 
therapy, the standard first-line treatment for non-resectable NSCLC has been cisplatin-
based chemotherapy regimens. However, standard chemotherapy regimens provide 
only modest clinical benefit with significant toxicities [5, 6]. 
Driver mutations in NSCLC 
Emerging treatment strategies for molecular subsets of NSCLC are based on 
specific driver mutations.  Tumor formation often involves the acquisition of multiple 
mutations that activate growth-enhancing genes (oncogenes) or inactivate growth-
inhibitory genes (tumor suppressor genes).  Epigenetic (non-mutational) abnormalities 
affecting oncogenes and tumor suppressor genes can also contribute to tumorigenesis 
[7].   
Despite harboring a complex set of genetic lesions contributing to tumor 
formation, cancers may rely on single-mutant oncogenes for survival, a concept known 
as  “oncogene addiction” [8].  Identification of mutant oncogenes that tumors rely on for 
growth and survival has therapeutic relevance as their dependence on mutant 
oncogenes can be exploited with targeted agents.  Perhaps the best case of clinical 
evidence of oncogene addiction is the targeting of the Bcr-Abl oncogene in chronic 
myeloid leukemia with the small-molecule inhibitor imatinib, which in one study induced 
a complete hematologic response in 95% of patients in whom previous interferon 
therapy had failed [9].   
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The most frequent driver mutations found in NSCLC affect K-Ras and EGFR, 
occurring in a mutually exclusive manner [10].  Oncogenic EGFR driver mutations are 
most frequently found in the NSCLC adenocarcinoma histology (95%) with incidence 
rates ranging from ~15% in Caucasians to ~50% in East Asians [11]. 
The EGFR signaling pathway 
The EGFR family of tyrosine kinases consists of four members: EGFR 
(HER1/ErbB1), HER2 (ErbB2), HER3 (ErbB3), and HER4 (ErbB4).  The EGFR signaling 
pathway (Figure 1) regulates physiological processes involved in cell proliferation, 
apoptosis, motility and neovascularization and its dysregulation has been associated 
with tumorigenesis [12]. 
Ligands of the EGF-receptor include EGF, TNFα, and amphiregulin, which bind 
specifically to EGFR.  Betacellulin, heparin-binding growth factor, and epiregulin bind to 
both EGFR and ErbB4.  Neuroregulins bind specifically to ErbB3 and ErbB4.  ErbB2 has 
no direct ligand but heterodimerizes with all other family members upon ligand binding 
[13, 14]. 
Upon ligand binding to the EGF-receptor, homo- or hetero-dimers are formed, 
leading to subsequent receptor activation of the intracellular kinase domain.  Tyrosine 
residues are phosphorylated within the cytoplasmic tail and serve as docking sites for 
proteins containing Src homology 2 (SH2) and phosphotyrosine binding (PTB) domains, 
resulting in the activation of intracellular signaling pathways [15, 16].  ErbB hetero-
dimerization allows for signal amplification and diversification but ErbB2 is the preferred 
heterodimer partner for all other ErbB receptors [17].  In addition, ErbB3 has an impaired 
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kinase domain, thus despite ligand binding, ErbB3 only functions when in complex with 
another ErbB family member [18]. 
The signaling pathways initiated by activated EGFR include the Ras/Raf/MEK 
pathway through either Grb2 or Shc adaptor proteins and PI3K/AKT by recruiting the 
p85 regulatory subunit [19].  EGFR signaling can also induce signal transducer and 
activator of transcription (STAT) factors [20]. 
 
Figure 1.  The EGFR signaling pathway.  In the absence of ligand, the receptor 
exists in monomeric form with the carboxyl-terminal tail of the receptor, auto-inhibiting 
the kinase domain.  Ligand binding promotes dimer formation, resulting in a 
conformational change which allows for intracellular trans-phosphorylation of tyrosine 
residues that serve as docking sites for signaling adapters, intracellular enzymes, or 
transcription factors.  As such, activated EGFR is involved in a myriad of signaling 
pathways involved in cell proliferation, survival, and migration.  Figure adapted from 
“Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for 
cancer therapy” by G. Pines, W. Kostler, and Y. Yarden, 2010, FEBS Lett, 2010. 
584(12): p. 2699-706. Copyright 2015 Federation of European Biochemical Societies.  
Adapted with permission [21]. 
5 
 
Mutant EGF-receptors escape negative regulation  
The most common mutations seen in EGFR-mutant NSCLC are an in-frame 
deletion in exon 19 (44%), which encodes the phosphate-binding loop, and a CTG to 
CGG point mutation in exon 21, which encodes the activation loop, resulting in the 
substitution of leucine by arginine at codon 858 (42%).  Other oncogenic mutations 
include a point mutation in exon 18, mainly G719X (X indicates A, C, S, or D), which 
occurs at a frequency of approximately 4%; insertion mutations in exon 20, which 
encodes the α-C helix (4%); and additional point mutations in exon 21 other than L858R 
occur at a frequency of approximately 3% [21] (Figure 2).  All of these mutations are 
believed to destabilize the inactive conformation, leading to increased basal kinase 
activity despite lack of ligand binding [22].  In addition, kinase-mutated EGF-receptors 
retain their ability to respond to growth factor ligands including EGF and TGFα, further 
augmenting signaling activity [23]. 
Exon 19 of EGFR encodes amino acids 729-761 and most exon 19 deletions 
occur between amino acids 746-753.  These deletions occur in the ß3 strand adjacent to 
the C-helix, and it has been proposed that the shortening of this strand favors the active 
conformation [24].  The L858R substitution locks the receptor in a constitutively active 
state due to the much larger charged side chain of arginine, which cannot be 
accommodated in the inactive state but is readily accommodated in the active 
conformation.  While much less common, G719X is believed to destabilize the inactive 




Figure 2.  Mutations in the kinase domain (exons 18-21) of EGFR and their 
associated frequencies of occurrence.  With the exception of T790M, these 
mutations are associated with sensitivity to EGFR-TKIs.  T790M is associated with 
resistance to EGFR-TKIs.  Figure adapted from “Tyrosine kinase inhibitors for 
epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: 
an update for recent advances in therapeutics” by C. Chung, 2016, J Oncol Pharm 
Pract, 22(3): p. 461-76.  Copyright 2016, SAGE Publications.  Adapted with permission 
[26]. 
 
Molecular predictors for response to TKIs  
Interestingly, the somatic mutations in the kinase domain of EGFR driving 
tumorigenesis have a clinical correlation with sensitivity and responsiveness to EGFR-
TKIs.  EGFR-mutants are 10- to 100-fold more sensitive to EGFR-TKIs versus their wild-
type counterpart [27-29].  An exception to this correlation is the exon 20 insertion 
mutation, which has been shown to be resistant to EGFR-TKI therapy [30]. 
First generation EGFR-TKIs, such as erlotinib and gefitinib, are effective 
reversible inhibitors of mutant EGFR, particularly those harboring EGFR exon 19 
deletions (EGFRdel19) or the EGFR exon 21 L858R mutation (EGFRL858R).  They are 
currently used as first-line therapies for the treatment of advanced EGFR-mutant NSCLC 
[31-34].  Erlotinib and gefitinib are quinazoline derivatives (Figure 3) that work as a 
reversible competitive inhibitor of adenosine tri-phosphate (ATP) for the ATP-binding 




Figure 3.  Chemical structure of first generation EGFR-TKIs gefitinib (left) and 
erlotinib (right).  Figure adapted from “The T790M mutation in EGFR kinase causes 
drug resistance by increasing the affinity for ATP” by Yun et al., 2008, Proc Natl Acad 
Sci U S A, 105(6): p. 2070-5.  Copyright 2008 National Academy of Sciences [35]. 
 
Patients harboring EGFR-mutant NSCLC when given EGFR-TKIs as a first-line 
therapy have experienced objective response rates of approximately 70% and a median 
progression-free survival (PFS) of 9-12 months, a significant improvement over 
chemotherapy in unselected NSCLC patients [36-38].  Multiple phase III trials have 
demonstrated EGFR-TKI therapy superior to chemotherapy alone in terms of response 
and PFS [31-33, 39, 40].  Additionally, durable responses have been achieved when 
EGFR-TKI therapy has been given in second or third-line settings as well [41-43]. 
Toxicities of EGFR-TKI therapy 
Toxicities of EGFR-TKI therapy are often less severe than those associated with 
traditional cytotoxic chemotherapy, but adverse events (AE) have occurred.  EGFR-TKI-
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associated rash, or follicular acneiform eruption, is the most common clinical AE (63%) 
and typically manifests on the face, shoulders, and back but tends to improve over time 
despite with continued EGFR-TKI therapy [44].  The second most common AE 
associated with EGFR-TKI therapy is diarrhea, which is thought to result from excess 
chloride secretion and is reported in 40 to 60% of patients.  However, diarrhea rarely 
results in disruption of treatment [45]. 
Acquired resistance to EGFR TKIs 
Despite initial response to EGFR-TKI therapy, most patients develop disease 
progression after 9-14 months of treatment.  Clinical criteria for diagnosis of acquired 
resistance have been proposed by Jackman et al., to include:  
1) Previous treatment with a single-agent EGFR-TKI to assess its therapeutic 
contribution to tumor response alone;  
2)  A tumor that harbors an EGFR mutation that induces EGFR-TKI sensitivity 
(exon 19 deletion, L858R, G719X, L861Q) OR objective clinical benefit from 
EGFR-TKI treatment defined as partial or complete response (Response 
Evaluation Criteria in Solid Tumors [RECIST] or World Health Organization 
[WHO] Handbook for Reporting Results of Cancer Treatment) or stable disease 
of greater than six months (RECIST or WHO) after EGFR-TKI initiation; 
3) Disease progression (RECIST or WHO) while on continuous treatment of 
EGFR-TKI within 30 days prior; and  
4) No intervening systemic therapy between EGFR-TKI cessation and initiation of 
new therapy [46]. 
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  Granted, some lung cancer patients who invariably develop acquired resistance 
to EGFR-TKI therapy do so through pharmacological mechanisms. However, the scope 
of my study is focused on biological resistance mechanisms, those that reflect the 
evolution of cancer cells in the presence of the drug.  Biological resistance mechanisms 
to EGFR-TKIs in EGFR-mutant NSCLC typically occur in four ways:  1) genetic 
alterations in the EGF-receptor render the drug ineffective at continued inhibition of 
EGFR signaling, 2) bypass signaling renders inhibition of EGFR alone insufficient to 
preserve tumor control, 3) modulation of downstream effectors of EGFR signaling that 
influence proliferation and apoptosis, and 4) phenotypic changes such as conversion to 
SCLC or epithelial-to-mesenchymal transition (Figure 4). 
The most clinically relevant mechanism of resistance to first generation EGFR-
TKIs is a secondary mutation in the EGFR kinase domain (T790M), which is found in 50-
65% of patients at the time of progression [47, 48].  The primary mechanisms by which 
T790M confers resistance to first-generation EGFR-TKIs such as gefitinib or erlotinib is 
increasing the binding affinity of ATP to the binding pocket, thereby reducing the potency 
of the ATP-competitive inhibitor [35].  Early work suggested steric hindrance by the bulky 
methionine substitution may contribute to T790M resistance [48, 49]. However, efficacy 
of structurally similar irreversible inhibitors suggests that reduced binding affinity is the 
primary contributor to resistance conferred by T790M [35].  
 It is also common for EGFR-mutant NSCLC to develop acquired resistance 
to TKI therapy by activating bypass signaling pathways that render inhibition of EGFR 
alone insufficient to control tumor growth.  The first described such mechanism was the 
amplification of MET, a proto-oncogene encoding a receptor tyrosine kinase (RTK) that 
binds to hepatocyte growth factor (HGF).  In this resistance mechanism, EGFR inhibition 
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is bypassed through amplified MET-mediated ERBB3 signaling [50].  High-level 
expression of HGF can induce a similar effect, but other growth factors such as EGF, 
TGFα, and insulin-like growth factor 1 (IGF1) were shown not to promote EGFR-TKI 
resistance [51].  Overexpression of CRKL, a signal transduction adaptor protein, has 
been reported to decrease sensitivity to EGFR-TKIs [52].  Increased FAS expression 
induces NF-κB signaling and has been observed in an acquired resistance cell line 
model [53].  Other bypass signaling tracks identified in patients with EGFR-TKI resistant 
tumors harboring drug–sensitive EGFR mutations include PIK3CA mutation, BRAF 
mutation, and HER2 amplification [47, 54-56]. 
 Induction of pro-apoptotic BCL2 interacting mediator of cell death (BIM) is 
essential for EGFR-TKI induced apoptosis [57], and pre-treatment BIM levels have been 
associated with responsiveness to EGFR-TKI [58]. However, germline BIM deletion 
polymorphisms in two independent cohorts of NSCLC patients failed to correlate 
objective response rates, progression-free survival, or overall survival between patients 
with or without a BIM deletion polymorphism [59]. 
Epithelial to mesenchymal transition (EMT) is a phenomenon in which epithelial 
cells gain mesenchymal characteristics such as loss of the cell-junction protein E-
cadherin and acquisition of vimentin expression and is associated with increased 
migratory potential [60].  Clinical evidence has shown phenotypic changes consistent 
with EMT at the time of EGFR-TKI resistance without any other identified mechanism of 
resistance [54, 61].  However, the frequency of occurrence in the patient population 
requires additional investigation due to the small size of re-biopsy series available for 
analysis.  Transformation to small cell lung cancer (SCLC) from adenocarcinomas has 




Figure 4. Molecular pathways involved in EGFR-TKI resistance.  Secondary 
mutations in the EGFR kinase domain diminish the ability of first generation EGFR-
TKIs to inhibit mutant EGFR signaling.  Up-regulation or activation of other RTKs such 
as AXL, MET, or HER2 can activate downstream effector pathways common to EGFR 
despite its continued inhibition.  RTK independent activation of downstream effector 
pathways can also occur by PTEN loss, activating PI3K and BRAF mutations.  
Epithelial-mesenchymal transition (EMT) as well as a small-cell phenotype transition 
also has been associated with EGFR-TKI resistance.  Adapted from “Mechanisms of 
resistance to EGFR targeted therapies” by G. Hrustanovic, B. Lee, and T. Bivona, 
2013, Cancer Biol Ther, 14(4): p. 304-14. Copyright © 2013 Taylor & Francis.  Adapted 
with permission [62].   
 
 
PI3K/AKT and ERK1/2 signaling regulate cell proliferation and survival 
As stated earlier, the signaling pathways initiated by activated EGFR include 
RAS/RAF/MEK/ERK1/2 and PI3K/AKT.  Reactivation of these pathways by bypass 
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signaling through alternative receptor tyrosine kinases (RTK) or modulation of 
downstream effectors can provide a mechanism for tumor cells to promote cell survival 
despite continued EGFR inhibition.   
 Reactivation of PI3K/AKT signaling by a RTK that bypasses EGFR can 
occur when the receptor is phosphorylated, providing a docking site for p85, a regulatory 
subunit of PI3K.  The catalytic subunit, p110, is recruited to the complex and the now 
active PI3K converts phosphatidylinositol (4,5)-phosphate [PI(4,5)P2] into 
phosphatidylinositol (3,4,5)-phosphate [PI(3,4,5)P3] [63].  This conversion allows for the 
recruitment of AKT which is then phosphorylated at residues T308 by PDK1, and S473 
by mTORC2 (also termed PDK2), initiating the mediation of downstream substrates that 
regulate cell cycle progression and survival [64]. 
 Reactivation of PI3K/AKT signaling can also occur by modulation of 
phosphatases that negatively regulate PI3K/AKT activity.  In multiple cancer types, it is 
common to see mutations that result in the loss-of-function of phosphatase and tensin 
homologue deleted on chromosome 10 (PTEN), or SH2-containing phosphatases 1 and 
2 (SHIP1 and SHIP2) [65, 66].  The function of these phosphatases is to convert 
[PI(3,4,5)P3] back to [PI(4,5)P2], to terminate signaling [67].  Mutations have also been 
reported in the catalytic subunit of PI3K that result in the constitutive activation of the 
enzyme [68]. 
 AKT signaling can promote cell survival and proliferation by multiple 
mechanisms [69] including: 
1) Phosphorylation and inhibition of forkhead family transcription factors 
(FOXO).  FOXOs promote growth inhibition and apoptosis by inducing the 
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expression of pro-apoptotic members of the BCL2 family and cyclin-
dependent kinase inhibitors; 
2) Activation of NF-κB and CREB transcription factors, inducing the 
expression of pro-survival genes; 
3) Directly phosphorylating and inactivating the pro-apoptotic BCL2 family 
protein, BAD;  
4) Activation of mTOR, a central regulator of cell metabolism, survival and 
proliferation; and, 
5) Maintaining mitochondrial integrity by activating hexokinase. 
In a similar fashion to AKT signaling, phosphorylation of RTKs provide docking 
sites for adapter proteins that initiate the RAS/RAF/ERK signal transduction pathway.  
The adapter protein growth factor receptor-bound protein 2 (GRB2) recruits the 
nucleotide exchange factor, son of sevenless (SOS), which in turn activates the GTPase 
RAS.  Activated RAS interacts with RAF, which phosphorylates MEK1 and MEK2, which 
in turn activate ERK1 and ERK2 [70].  However, RAF activation is complex and involves 
multiple GTPases, kinases, and phosphatases. 
The onset and duration of ERK signaling is regulated, in part, by phosphatases.  
For example, protein phosphatase 2A (PP2A) can regulate the RAF/MEK/ERK pathways 
in a positive manner by dephosphorylating negative regulatory sites of RAF, or in a 
negative manner by dephosphorylating ERK-dependent sites of RAF [70]. 
Scaffolding proteins, such as SHOC2—which facilitates the association of the 
RAS/RAF complex [71], can also have a critical role in modulating ERK signaling.  It has 
been recently suggested that regulation of SHOC2 is mediated through ubiquitination by 
the E3 ubiquitin ligase HUWE1 [72]. 
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RAS/RAF/MEK/ERK signal transduction ultimately leads to modulation of 
transcription factors that regulate cell cycle progression and apoptosis.  Cyclins, cyclin-
dependent kinases, cyclin-dependent kinase inhibitors, cytokines and growth factors, 
BCL2-family proteins, and caspases can all be influenced by ERK-activated transcription 
factors.  ERK can directly phosphorylate and activate c-JUN [73], Ets-like protein [74], 
and c-MYC [75].  Phosphorylation of RSK, a downstream kinase of ERK, activates the 
transcription factor, CREB [76].  The transcription factor, NF-κB, can be induced by 
ERK-mediated activation of IKK.  IKK phosphorylates Inhibitor of NF-κB proteins leading 
to their subsequent degradation which allows NF-κB to translocate to the nucleus for 
gene transcription [77]. 
BIM induction is critical for EGFR-TKI response 
BIM (also known as BCL2L11) belongs to a subgroup of BCL2-family proteins 
that contain a BH3 domain and can trigger apoptosis when overexpressed [78].  
Mitochondrial outer membrane permeabalization, the hallmark of the intrinsic apoptotic 
pathway, occurs when the balance of BCL2 family proteins favor the oligermization of 
the BCL2 family effectors BAX and BAK.  Inhibition of BAX and BAK can occur in 3 
ways: 1) pro-survival proteins, such as BCL-XL bind to BAX at the outer mitochondrial 
membrane and translocate it to the cytosol, 2) pro-survival proteins sequester BH3-only 
proteins to prevent direct activation of BAX and BAK, and 3) pro-survival proteins bind to 
activated BAX and BAK to prevent their oligermization [79].  A schematic representation 
of BC2-family protein interactions is shown in Figure 5.   
BIM exerts its pro-apoptotic characteristics by either inhibiting pro-survival BH3 
members or directly activating BAX or BAK [80].  Ultimately, the balance of the BCL2-
family pro-survival and pro-apoptotic proteins determines the cell fate.  This dynamic 
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balance relies heavily upon ubiquitin-mediated proteasome degradation.  For example, 
MCL1, a BCL2 pro-survival protein can rapidly induce apoptosis upon its degradation 
due to loss of its anti-apoptotic function, and overexpression of MCL1 has been linked to 
poor prognosis in multiple cancer types [81, 82].  BIM is also subject to proteasome 
mediate degradation.  At the translational level, BIM can be phosphorylated and rapidly 
degraded by the proteasome.  Evidence suggests that ERK1/2-mediated 
phosphorylation at Ser69 is both necessary and sufficient for proteasome-mediated 
degradation of BIM [83].  
 
Figure 5.  Interactions within the BCL2 
family.  The BCL2 family of proteins consists 
of the pro-apoptotic BAX/BAK proteins, pro-
apoptotic BH3-only proteins, and pro-survival 
proteins.  The pro-survival proteins inhibit the 
activity of the pro-apoptotic proteins.  BH3-
only proteins promote apoptosis by 1) directly 
activating BAX/BAK or 2) inhibiting the pro-
survival proteins.  Figure adapted from 
“Building blocks of the apoptotic pore: how 
Bax and Bak are activated and oligomerize 
during apoptosis” by D. Westphal, R. Kluck, 
and G. Dewson, 2014, Cell Death Differ. Feb; 
21(2): 196–205.  Copyright © 2013, Nature 




Three major splice variants exist for BIM protein—short, long, and extra-long 
(BIMS, BIML, and BIMEL, respectively) with BIMEL being the most predominant in the 
majority of cell types [78].  Regulation of BIM expression levels can occur at both the 
transcriptional and translational level.  Inhibition of PI3K leads to FoxO3a-dependent 
transcriptional activation of BIM [84], but comparison of BIM mRNA and BIM proteins 
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suggests that rapid expression of BIM protein cannot solely be attributed to increases in 
BIM mRNA following PI3K inhibition [85].  Upon reactivation of AKT, FoxO3a is 
phosphorylated at Thr32, Ser253 and Ser315, which sequesters FoxO3a to the 
cytoplasm, preventing its nuclear translocation and subsequent transcription of target 
genes including BIM [86]. 
Higher levels of BIM expression are associated with lower risk of mortality and 
disease progression in EGFR-mutant lung cancer patients [87] and suppression of BIM 
expression is sufficient to confer in vitro EGFR-TKI resistance [88, 89].  Consistent with 
these findings, patients with BIM polymorphism deletions (lack pro-apoptotic BH3 
domain), which occur in approximately 13% of the East Asian population but are non-
existent in African and European populations, have poor clinical outcomes when treated 
with EGFR-TKI [90]. 
Thus, reactivation of AKT and ERK1/2, as well as modulation of enzymes that 
target BCL2-family proteins for proteasome-mediated degradation, may promote EGFR-
TKI resistance by providing a mechanism to evade apoptosis via reduced BIM 
expression. 
The ubiquitin-proteasome system 
The ubiquitination of proteins can have vast effects on cell physiology and signal 
transduction, so it stands to reason they are relevant to tumorigenesis and resistance to 
targeted therapies.  Targeting proteins for proteasomal degradation by lysine 48-linked 
polyubiquitin has been well characterized [91].  Ubiquitylation using other polymerization 
sites, such as K63, can also have non-degradative function, such as membrane 
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trafficking, DNA repair and replication, and inflammatory response, through mono-
ubiquitination [92] or poly-ubiquitination of non-K48 chains [93]. 
The ubiquitination machinery consists of three types of enzymes (E1, E2, and 
E3) that act sequentially to covalently attach ubiquitin onto target substrates via an 
isopeptide bond.  The role of the E1 enzyme is to activate the C-terminal glycine residue 
of ubiquitin in an ATP-dependent mechanism.  Activated ubiquitin is then transferred to a 
cysteine residue of the E2 enzyme.  The E3 enzyme catalyzes the linkage of the 
ubiquitin to a lysine residue of the substrate protein.  Specificity of the target substrate is 
determined by the E3 enzyme [91]. 
  Classes of E3 ubiquitin ligases are characterized by their conserved structure 
and the mechanism by which ubiquitin is transferred from the E2 enzyme to the 
substrate.  Really interesting new gene (RING) and Skp1–Cul1–F-box-protein (SCF) 
families of E3 ubiquitin ligases catalyze the direct transfer of ubiquitin from the E2 to the 
target substrate.  The homology to E6AP C-terminus (HECT) and RING-between-RING 
(RBR) family of E3 ubiquitin ligases, in contrast, possess intrinsic catalytic activity.  In a 
two-step reaction, the ubiquitin is first transferred to the E3 enzyme, and then directly 
transferred onto the substrate by the E3 enzyme [94].  A schematic representation of the 






Figure 6.  The ubiquitin cascade and chain formation.  First, an ATP-dependent 
reaction results in a thioester bond between the ubiquitin and the active site of the E1 
enzyme.  Ubiquitin is then transferred to the active site of the E2 enzyme in a 
transthioesterification reaction.  Ring E3 enzymes bind to both the ubiquitin-attached 
E2 and the substrate and catalyze the attack of the substrate lysine.  HECT and RBR 
E3 enzymes are involved in a two-step reaction involving the formation of a thioester 
with the E3 enzyme, followed by an attack of the substrate lysine.  Figure adapted 
from “New insights into ubiquitin E3 ligase mechanism” by C. Berndsen and C. 
Wolberger, 2014, Nat Struct Mol Biol. Apr;21(4):301-7. doi: 10.1038/nsmb.2780.  
Copyright © 2014, Nature Publishing Group.  Adapted with permission [94]. 
 
 
Acquisition versus selection model of acquired resistance  
One could propose two models from which acquired resistance mechanisms 
develop.  The selection model assumes that resistant clones exist prior to treatment that 
are selected for by EGFR-TKIs.  The acquisition model presumes that novel genetic or 
epigenetic alterations occur during the course of EGFR-TKI treatment.  Based on initial 
reports of pre-progression samples lacking EGFRT790M, it was believed that such 
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alterations were the result of “acquisition” only after exposure to EGFR-TKIs [48, 49].  
Another group, however, found that a small fraction of cells were EGFRT790M+ within a 
treatment-naïve tumor and experienced a shorter time to progression, suggesting that 
while the tumor initially responded to EGFR-TKI therapy, the eventual disease 
progression was due to the selection of the EGFRT790M clones present within the tumor.  
There has been much debate over whether the “acquisition” or “selection” models of 
acquired resistance to EGFR-TKI therapy (Figure 7) is the likely cause of eventual 
disease progression [95]. 
 
 


















Figure 7. “Acquisition” versus “selection” model. T790M and MET amplification 
mechanisms of acquired resistance after EGFR-TKI treatment in TKI-naïve EGFR-
mutant NSCLC.  Figure adapted from “Acquired resistance to epidermal growth factor 
receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the 
epidermal growth factor receptor pathway” by K. Nguyen, S. Kobayashi, and D. Costa, 






Addressing resistance in the clinic 
 There are a number of emerging strategies and ongoing clinical studies 
that aim to overcome EGF-TKI resistance in the clinic. However, currently the only 
approved therapy is directed at T790M-mediated resistance. 
To address the T790M mechanism of acquired resistance, second generation 
EGFR-TKIs—including afatinib, neratinib, and dacomitinib were developed to irreversibly 
bind to EGFR and were shown to more effectively inhibit T790M than first generation 
EGFR-TKIs [97-99].  However, second generation EGFR-TKIs were not received well in 
the clinic, with response rates below 10% [100, 101].  The likely explanation for such 
disappointing results is the lowered IC50 against the wild-type receptor which resulted in 
significant toxicities at doses required to effectively inhibit T790M [97, 99, 102].  
Recently, third generation EGFR-TKIs have been developed to target EGFRT790M, 
including osimertinib, a mono-anilino-pyrimidine compound (Figure 8), which received 
FDA approval in November 2015, the only third generation EGFR-TKI to do so to date.  
This class of inhibitors forms an irreversible covalent bond at Cys797 in the ATP binding 
site [103] yet largely spares wild-type EGFR, thus decreasing toxicities and allows for 





Figure 8.  Chemical structure of osimertinib.  Figure adapted from “AZD9291, an 
irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in 
lung cancer” by D. Cross et al., 2014, Cancer Discov, 4(9): p. 1046-61. ©2014 
American Association for Cancer Research.  Adapted with permission [104]. 
 
 
Because osimertinib is effective against sensitizing EGFR mutations and is also 
associated with reduced AE associated with first generation TKIs, it is now being 
investigated for use in first-line therapy for the treatment of metastatic EGFR-mutant 
positive NSCLC (AURA phase II expansion cohort, CllinicalTrials.gov, NCT01802632).  
Two expansion cohorts were given first-line osimertinib monotherapy, and the reported 
overall response rate (ORR) was 77%.  The median progression-free survival was 19.3 
months overall, and 3% and 7% of patients developed a ≥3 grade skin rash and ≥3 
diarrhea, respectively [105].  A phase II randomized study is ongoing comparing 
osimertinib with gefitinib and erlotinib as first-line therapies in patients with advance 
EGFR-mutant NSCLC (FLAURA study, ClinicalTrials.gov, NCT02296125). 
Clinical observations have shown that some patients may benefit from 
retreatment of EGFR-TKI after a period of cessation [106].  This, however, is not a 
suitable strategy for all patients because a study of patients with acquired EGFR-TKI 
resistance found that 25% experienced accelerated disease progression immediately 
following cessation of treatment [107].  A possible explanation is that subclones within 
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the resistant tumor may remain drug-sensitive but held in a dormant state that rapidly 
expand upon release of the selective pressure of the EGFR-TKI [108].   
Dual inhibition of the extracellular domain of EGFR with monoclonal antibodies 
and the intracellular domain of EGFR with tyrosine kinase inhibitors have been 
suggested to provide clinical benefit for resistant tumors mediated by altered drug target 
mutations such as T790M [109].  Unfortunately, a high incidence of AE may limit its 
clinical applicability [110].  
Heat-shock protein 90 (HSP90) is a molecular chaperone protein that has been 
shown to play a role in maintaining the active conformation of EGF-receptors and 
preventing Cbl-mediated ligand-induced receptor down-regulation [111].  Inhibition of 
HSP90 in combination with EGFR inhibition is being explored as a therapeutic approach 
for patients with resistant tumors.  However, a current phase I/II study was met with 
significant toxicities and failed to meet its primary endpoint [112]. 
Anti-angiogenesis agents such as bevacizumab have recently been investigated 
for clinical efficacy when combined with erlotinib as a first-line therapeutic strategy in 
EGFR-mutant NSCLC patients.  A randomized phase II study found that combining 
erlotinib plus bevacizumab increased PFS (16.0 months) compared to erlotinib alone 
(9.7 months).  Although there was no significant changes in overall survival, tumor size 
was significantly reduced in erlotinib plus bevacizumab patients versus erlotinib alone 
[113].  Additional clinical trials are currently underway to further investigate its use as a 
first-line regimen (ClinicalTrials.gov, NCT01532089 and NCT01562028). 
Targeting immune checkpoints such as PD-1 and PD-L1 has emerged as a 
promising strategy in lung cancer immunotherapy.  Nivolumab, a PD-1-blocking 
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antibody, has received FDA approval for the treatment of squamous cell lung cancer, but 
further investigation is needed to determine the efficacy of nivolumab as a monotherapy 
or in combination with EGFR-TKIs in NSCLC.  A phase I trial of nivolumab, a PD-1-
blocking antibody found patients that responded obtained durable results [114], but 
correlating response to EGFR status remains controversial [114, 115] 
Despite the success of EGFR TKIs as front-line treatment, acquired resistance is 
inevitable and remains a significant challenge in the management of patients with 
EGFR-mutant NSCLC.  Therefore, understanding the molecular mechanisms of 
acquired drug resistance remains a critical step in overcoming drug-resistant tumors in 
the clinic. 
Identification of modifiers of EGFR signaling dependence 
Genetic screens using libraries of short hairpin RNA (shRNA) and open reading 
frames (ORFs) are powerful approaches for identifying novel genes that regulate various 
phenotypes of cancer cells [116, 117]. Recently, the CRISPR (clustered regularly 
interspaced short palindromic repeats) and CRISPR-associated endonuclease Cas9 
system from Streptococcus pyogenes has been harnessed for editing genome or 
introducing loss-of-function mutations in eukaryotic cells [118, 119]. The Cas9 nuclease 
can be guided by an engineered single-guide RNA (sgRNA) to cause double-stranded 
cleavage of a complementary target DNA sequence such as within a coding exon [119]. 
If the DNA cleavage is repaired by error-prone non-homologous end joining (NHEJ), 
insertion/deletion (indel) mutations likely occur, resulting in a coding frameshift, 
generation of premature stop codon, and initiation of nonsense-mediated decay (NMD) 
of the transcript [119]. Recent studies have successfully utilized Cas9/sgRNA system to 
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carry out high-throughput genetic knockout screens to identify novel genes that modify 
dependence on mutant BRAF in melanoma cells [120].  
Tumor heterogeneity and the complicated mechanisms involved in EGFR-TKI 
resistance have impeded the development of successful solutions for overcoming this 
resistance.  The use of genetic screens can be used to identify genes that have a critical 




Genome-scale CRISPR-Cas9 knockout screen 
To identify candidate genes, the Cheung lab applied the RNAi gene enrichment 
ranking (RIGER) algorithm that used three complementary methods, including: 1) the 
rank of the top two sgRNAs targeting each gene; 2) the rank of the top two sgRNAs 
targeting each gene to generate a weighted sum score; and 3) the rank of all sgRNAs 
targeting each gene using the Kolmogorov-Smirnov (KS) statistics [116]. Among the top 
100 highest-ranking candidates nominated by each gene-ranking method, the Cheung 
lab identified 23 candidate genes that scored in all three analyses. 
These 23 highest-ranking candidates included genes previously reported to 
confer resistance to EGFR-TKIs when expression is suppressed, such as PTEN, NF1, 
NF2, TSC1, TSC2, and MED12 [121-125].  The 23 highest ranking candidates of the 
sgRNA screen also revealed novel candidates that have not been implicated in EGFR 
TKI resistance, such as HUWE1 (Figure 9), BCL2-associated X protein (BAX) [126], NF-




Figure 9. sgHUWE1 is enriched in HCC827 cells positively selected for by 
erlotinib.  Log fold change of 5 sgRNAs targeting different regions of the HUWE1 
gene.  HCC827 cells were transduced with sgRNA library, treated with erlotinib or 
DMSO for 17 days and enriched sgRNAs were identified by next-generation 
sequencing. 
 
Expression profiling of HUWE1-suppressed HCC827 cells 
 The Cheung lab also performed RNA expression profiling of HUWE1-
suppressed HCC827 cells after erlotinib treatment.  Doxycycline-inducible shRNA was 
used for gene suppression and 3 replicates of each treatment group were treated with 
erlotinib or DMSO control for 24 hours.  The treatment groups were as follows: 1) No 
Dox, No erlotinib; 2) No Dox, Plus erlotinib; 3) Plus Dox, No erlotinib; and 4) Plus Dox, 
Plus erlotinib.  After the treatment period, total cellular RNA was extracted and samples 
were analyzed on an Illumina HumanHT-12v4.0 bead array at the Hollings Cancer 
Center Genomics Shared Resource at the Medical University of South Carolina.  The 
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Rationale for the study of HUWE1 
The HECT, UBA, and WWE domain-containing protein 1 (HUWE1), also known 
as Mule or ARF-BP1, is a HECT (homologous to E6-AP carboxyl terminus)-domain 
containing ubiquitin E3 ligase. We selected HUWE1 for further study because HUWE1 
has been implicated in regulation of cancer cell proliferation and survival but its role in 
lung cancer response to EGFR-targeted therapy has not been studied.   
HUWE1 has been reported to frequently misregulated by overexpression in 
multiple tumor types including lung cancer (~10%), but was not found to be correlated 
with overall survival [128].  Mechanistically, HUWE1 has been shown to ubiquitinate and 
regulate the stability or activity of multiple prominent substrates that are involved in the 
regulation of apoptosis (such as p53, MCL1), cell proliferation (c-MYC, MIZ1, N-MYC), 
DNA damage repair (DNA polymerases  and ), B-cell homeostasis [129, 130], and 
neural differentiation (N-Myc) [131]. For example, HUWE1 ubiquitinates the anti-
apoptotic protein MCL-1 for proteasome-dependent degradation [81]. Suppression of 
HUWE1 in U2OS osteosarcoma cells stabilizes MCL-1 proteins and protects cells from 
cisplatin-induced apoptosis [81]. HUWE1 also ubiquitinates MIZ1, a c-MYC binding 
partner that represses transcription of several cyclin-dependent kinase inhibitors [132].  
HUWE1 has been shown to exert growth inhibitory effects on thyroid cancer cells 
through, in part, regulating p53 stabilization [133].  Inactivation of Huwe1 in skin of mice 
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enhances carcinogen- or Ras-induced tumorigenesis due to accumulation of c-
MYC/MIZ1 complexes and down-regulation of p21CDKN1A and p15ARF4B [134].  Recently, 
HUWE1 has been shown to mediate ubiquitination of SHOC2, a scaffold protein that 
coordinates activation of RAS-RAF1-ERK1/2 signaling cascade [72]. Suppression of 
HUWE1 in COS-1 fibroblast cells stabilizes SHOC2 proteins and increases RAF1 activity 
in response to EGF stimulation [72].  HUWE1 also regulates TIAM1 in lung epithelial 
cells, disassociating cell-cell junctions thereby promoting migration and invasion [135]. 
With many putative functions, the role of HUWE1 in tumorigenesis is currently 
still debatable as its determination of cell fate has been described to have both pro- and 
anti-apoptotic consequences [136].  It remains unexplored whether HUWE1 levels 
modulate EGFR dependence in EGFR-mutant lung cancer cells.  The identification of 
multiple negative regulators of PI3K-AKT-mTOR signaling pathway in the sgRNA screen 
suggests that re-activation of this survival pathway allow HCC827 cells to escape from 









Hypothesis:  I hypothesize that suppression of HUWE1 confers EGFR-TKI resistance 
by reactivating AKT and ERK1/2 signaling pathways to attenuate apoptotic cell death 
and increase cell proliferation. 
Specific Aim #1:  Assess the in vitro effects of suppressing HUWE1 by shRNAs on 
proliferation and survival in response to EGFR-TKI.  In preliminary data, EGFR-
mutant and EGFR-TKI-sensitive cells were enriched with multiple sgRNAs targeting 
HUWE1 when under positive selection by erlotinib treatment. These results suggest that 
its loss-of-function may contribute to EGFR-TKI resistance by allowing signaling to 
continue in the presence of the inhibitor.   I will validate the phenotype observed in the 
sgRNA screen and elucidate underlying mechanisms to better characterize the role of 
HUWE1 in the modulation of EGFR dependence in EGFR-mutant NSCLC. 
Task #1:  Establish stable HCC827 cell line expressing inducible shHUWE1 and assess 
the following: 
1. Effects on cell viability in response to erlotinib 
2. Effects on apoptosis in response to erlotinib by Annexin V FACS analysis 
3. Effects on proliferation in response to erlotinib by BrdU incorporation 
during DNA synthesis 
Task #2:  Investigate mechanism of drug resistance by: 
1. Examining protein levels downstream of EGFR and of HUWE1 
substrates such as phospho-AKT, phosphor-ERK1/2 and MCL1, SHOC2 
2. Gene-set enrichment analysis of transcriptional profiling of HUWE1 





Cell culture:  HCC827 cells were cultured in RPMI medium (Corning) 
supplemented with 10% fetal bovine serum (FBS; Corning) and 1× Penicillin-
Streptomycin (Corning). Tetracycline-free FBS (Clontech) was used when tetracycline 
inducible expression system (TetOn) was applied. 293T packaging cells were cultured in 
DMEM medium (Corning) supplemented with 10% FBS (Corning). 
Chemicals:  Erlotinib, BEZ235 and AZD6244 were purchased from Selleck 
Chemicals. All chemicals were dissolved in DMSO. 
Generation of stable cell line expressing TetOn-shHUWE1:  The shRNAs 
were cloned into pLKO-TetOn-shRNA vector [52] (Table 1).  Freshly thawed 293T cells 
were passaged at least three times before viral production and then 1×106 were seeded 
onto 6-cm dishes in 4.5 mL of DMEM + 10% FBS for 24 hours.  Opti-MEM (Fisher 
Scientific) and Mirus TransIT-LT1 transfection reagent (Fisher Scientific) were added to 
1 µg of pLKO-TetOn-shHUWE1 or 1 µg pLKO-TetOn-Control, 1 µg of psPAX2 
packaging plasmid, and 0.4 µg of VSVG envelop plasmid according to manufacturer’s 
directions.  The transfection mixture was incubated at room temperature for 20 minutes 
before adding drop wise to the 293T cells.  The following day, the media was replaced 
with fresh DMEM + 10% FBS and incubated for an additional 24 hours.  Virus was then 
harvested by passing supernatant through a 0.45 µm filter (VWR). 
 One day prior to infection, HCC827 cells were seeded in 10-cm dishes to 
30-50% confluence at the time of infection.  At the time of infection, 1 mL of media was 
replaced with 1 mL of pLKO-TetOn-HUWE1 or control virus and media was 
supplemented with 8 µg/mL of polybrene and incubated for 24 hours.  An additional non-
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infected plate was used as a selection control.  Media was then removed and replaced 
with fresh media supplemented with 2 µg/mL puromycin.  Cells were selected for 6 days, 
changing media + puromycin every three days. 
 
Table 1. shRNA targeting sequences for HUWE1 knockdown 
shRNA Target sequence 




Viability of HCC827 cells expressing shHUWE1 in response to EGFR-TKI:  
HCC827 cells stably expressing with pLKO-TetOn-control shRNA or pLKO-TetOn-
shHUWE1 were cultured, as previously described. Afterwards, 3,000 cells were plated 
into each well of 96-well plates in the presence or absence of doxycycline (0.5 μg/mL) 
for 72 hours.  Cells were then treated with increasing concentrations of erlotinib (0, 
0.001, 0.0033, 0.01, 0.033, 0.1, 0.33, 1, 3.3, and 10 μM) for another 72 hours. The cell 
viability was determined by using CellTiter-Glo luminescent cell viability assay 
(Promega) according to manufacturer’s instructions. Luminescence (560 nm emission 
wavelength) was quantified on a SpectraMax M3 microplate reader (Molecular Devices).   
Apoptosis in response to EGFR-TKI:  HCC827 shHUWE1 cells (2.5×105) were 
seeded into 6-cm culture dishes in the presence or absence of doxycycline (0.5 µg/mL) 
for 3 days. Erlotinib (1 µM) or an equal volume of DMSO was added and incubated for 
24 hours. Cells were then trypsinized and collected together with the cell culture 
supernatant. After centrifugation at 1500 rpm for 5 min, cell pellets were rinsed with cold 
1x PBS. After another centrifugation, cells were resuspended in Annexin binding buffer 
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and counted. In a volume of 200 μL, 2×105 cells were mixed with 10 μL of Annexin V/ 
AlexaFluor 488 conjugate (Life Technologies) and incubated for 15 minutes at room 
temperature. After staining, 200 µL of Annexin binding buffer and 4 μL of propidium 
iodide (100 µg/mL) (Fisher Scientific) were added and incubated for another 20 minutes. 
Cells were immediately analyzed by flow cytometry on FACSAria IIu (BD Biosciences) 
and data was analyzed using FACSDiva™ 6 software (BD Biosciences). 
Cell Proliferation in response to EGFR-TKI:  HCC827 shHUWE1 cells 
(2.5×105) were seeded into 6-cm culture dishes in the presence or absence of 
doxycycline (0.5 µg/mL) for 3 days. Erlotinib (1 µM) or equal volume of DMSO were 
added to fresh media and incubated for 24 hours.  BrdU (10 µM) was added to the 
culture medium and cells were incubated for 1 hour at 37°C.  Cells were then trypsinized 
and collected, then centrifuged at 1500 rpm for 5 minutes followed by a wash with 1x 
PBS and re-centrifugation.  Cells were fixed by adding 5 mL of 70% ethanol pre-chilled 
to -20°C drop-wise to cell pellet while vortexing.  Cells were incubated for 20 min at room 
temperature then stored at 4°C overnight.  Cells were then washed in 1x PBS.  After 
centrifugation at 1500 rpm for 5 min, cell pellet was resuspended in 2 mL HCL (2 M) an 
incubated at room temperature for 20 minutes.  After another wash and centrifugation, 
cell pellet was resuspended in 2 mL of Na2B4O7  (0.1M) and incubated for 2 minutes.  
Immunoblot protein analysis:  To assess protein content of HCC827 cells 
expressing shHUWE1 in response to EGFR-TKI, an immunoblot analysis was 
performed.  In 6-cm dishes,  2.5×105 cells were seeded in the presence or absence of 
doxycycline (0.5 µg/mL) for 3 days.  Erlotinib (0.1, 1, or 10 µM) or DMSO was added to 
culture media for 6 hours.  The media was then aspirated, and cells were rinsed twice 
with 5 mL ice-cold PBS.  Cells were collected in 60 µL RIPA lysis buffer + Halt 
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phosphatase inhibitors (Pierce using a cell scraper and transferred to a 1.5 mL tube and 
incubated on ice for 20 minutes.  Samples were then centrifuged at 13500 rpm for 20 
minutes at 4°C, and supernatant was transferred to a new 1.5 mL tube and gently 
vortexed.   Protein concentrations of samples were assessed using BCA protein assay 
(Pierce).  A volume of 100 µL of BCA protein assay reagent (mixed according to 
manufacturer’s instructions) was added to each well in a 96-well plate.  0, 1, 2, 4, and 6 
µL of a 2 mg/mL standard of BSA was used to generate a standard curve.  A volume of 
2 µL of the samples of unknown concentration was added to each well.  The plate was 
incubated for 30 minutes in the dark at 37°C and then immediately read on a M3 
SpectraMax microplate reader (Molecular Devices) at a primary wavelength of 540 nm to 
determine protein concentrations. 
 For immunoblot analysis, 25 µg of protein sample was added to a tube 
containing SDS sample buffer (Life Technologies) plus 10% ß-mercaptoethanol and 
boiled for 5 minutes.  The proteins in the sample were separated using 4-12% NuPage 
Bis-Tris precast polyacrylamide gels (ThermoScientific) in running buffer containing 
MOPS SDS running buffer (Life Technologies) and run at 140 volts for 90 minutes.  The 
gels were removed from their cast and transferred to a nitrocellulose membrane using 
the iBlot dry blotting system (ThermoScientific) according to manufacturer’s instructions.  
For HUWE1 protein analysis, gels were incubated for 10 minutes in a buffer containing 
NuPage Transfer buffer (Invitrogen) and 0.25% methanol prior to transfer.  To reduce 
non-specific binding, membranes were incubated in 10% milk in PBST for 1 hour.  After 
blocking, membranes were washed 3 times for 5 minutes with PBST and then incubated 
with primary antibodies and incubated overnight at 4°C with gentle rocking.   
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Antibodies were diluted in 5% milk as follows:  HUWE1 (1:10000, Bethyl); EGFR 
(1:2000, Cell Signaling); p-ERK1/2 (1:2000, Cell Signaling); total ERK1/2 (1:4000, Cell 
Signaling); p-AKT 1:20000, Cell Signaling); total AKT (1:4000, Cell Signaling); p-RAF1; 
total RAF1; SHOC2; c-MYC (1:200, Santa Cruz); MIZ1 (1:200, Santa Cruz); BIM 
(1:2000, Cell Signaling); and MCL1 (1:1000, Cell Signaling).  Membranes were then 
washed with PBST 3 times for five minutes each.  Anti-rabbit and anti-mouse HRP-
linked secondary antibodies (Bio-Rad) were diluted in 5% milk (1.5:10000 for all).  Blots 
were incubated in appropriate secondary antibody at room temperature for 1 hour and 
30 minutes with gentle rocking.  Blots were covered with Enhanced Chemiluminescence 
Plus blotting substrate (Pierce) for five minutes to activate horseradish peroxidase.  
Proteins were visualized using CL-Xposure autoradiography film (Pierce) at various time 
exposures developed on an automatic developer (Kodak).  To assess loading control, 
membranes were stripped by washing membranes in PBST for five minutes followed by 
distilled water for five minutes and then incubated with 0.2 M NaOH for seven minutes.  
After washing with distilled water (three times for 5 minutes each) and PBST (once for 5 
minutes), blots were incubated with HRP-conjugated ß-actin (Bio-Rad) diluted in 5% milk 
at 1:2000 for 30 minutes at room temperature with gentle rocking.  The blots were then 
washed and developed as previously described.   
 Real-time quantitative Reverse-Transcription PCR:  HCC827 cells 
stably expressing with pLKO-TetOn-control shRNA or pLKO-TetOn-shHUWE1 were 
cultured, as previously described, in 6-cm dishes.  After aspirating off media, total RNA 
was extracted with 1 mL TRIzol reagent (Life Technologies).  After incubating for 5 
minutes at room temperature, 0.2 mL of chloroform (Sigma) was added followed by 15 
seconds of vigorous shaking.  Tubes were incubated for additional 3 minutes at room 
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temperature followed by centrifugation at 12000xg for 10 minutes at 4°C. The colorless 
layer was then transferred to a new 1.5 mL tube and 0.5 mL of isopropanol (Sigma) was 
added and incubated for 10 minutes followed by centrifugation at 12000xg for 10 
minutes at 4°C.  Supernatent was removed, 1 mL of 75% ethanol was added, and the 
tube was inverted 5 times before centrifugation at 7500xg for 5 minutes at 4°C.  Ethanol 
was then removed and pellet was dissolved in 50 µL of ultra-pure water (Gibco).  First-
strand cDNA was synthesized from 2 µg total RNA using Maxima First Strand cDNA 
Synthesis Kit (ThermoScientific) according to manufacturer’s instructions.  For 
quantitative PCR, each primer set (Table 2) was plated in triplicate in a 96-well plate with 
the use of Maxima SYBR Green qPCR Master Kit (ThermoScientific) according to 
manufacturer’s instructions.   
Table 2.  Primer sequences for qPCR analysis






5’- CTGGCTAGACTCCGACG-3’ 67.26°C 
 
Plates were read on a Roche LightCycler480 with the following conditions:  1) 
after pre-incubation to 95°C, amplification occurred in a series of 45 cycles of 15 
seconds at 95°C then 60 seconds at 60°C, 2) melt-curve analysis was performed 
immediately following amplification by denaturing at 95°C for 5 seconds, annealing at 
65°C for 1 minute, then ramping temperature to 97°C at a rate of 0.11°C/s with 5 
acquisitions per °C, and 3) cooling of plate to 40°C.  The mean cycle threshold was used 
for comparative cycle threshold analysis (ABI User Bulletin #2).  All mRNA levels were 
normalized to GAPDH. 
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TKI drug combination to reverse shHUWE1-mediated resistance:  HCC827 
cells stably expressing with pLKO-TetOn-control shRNA or pLKO-TetOn-shHUWE1 
were cultured as previously described before 3,000 cells were plated into each well of 
96-well plates in the presence or absence of doxycycline (0.5 μg/mL) for 72 hours.  Cells 
were then treated with increasing concentrations of erlotinib (0, 0.001, 0.0033, 0.01, 
0.033, 0.1, 0.33, 1, 3.3, and 10 μM) alone, erlotinib + 0.5 µM BEZ235, erlotinib + 0.5 µM 
AZD6244, or erlotinib + 0.5 µM BEZ235 + 0.5 µM AZD6244 for another 72 hours. The 
cell viability was determined by using CellTiter-Glo luminescent cell viability assay 
(Promega) as described previously. 
Gene set enrichment analysis:  Raw data files of array values were obtained 
from the lab of Dr. Cheung for gene set enrichment analysis.  The data set contained 
reads from three replicate experiments of 4 treatment groups: 1) No Dox, No erlotinib; 2) 
No Dox, Plus erlotinib; 3) Plus Dox, No erlotinib; and 4) Plus Dox, Plus erlotinib.  The 
raw data file was processed for GSEA analysis using the Gene Pattern (Broad Institute) 
“PreprocessDataset” module with default values.  The processed data was loaded into 
the GSEA software v2.2.0 (Broad Institute) along with the gene set “c2all.v5.0”.  The 
phenotypes “Plus Dox, Plus erlotinib” versus “No Dox, Plus erlotinib” were analyzed 
using default settings with the exception of “Collapse dataset to gene symbols” was set 
to “false”. 
Statistical Analysis:  Western blotting was analyzed by densitometry using 
ImageJ software.  Significance of changes in cell viability, apoptotic cell populations, and 
cell-cycle populations will be determined by two tailed, unpaired student’s t-test.  P < 





Inducible shRNA targeting HUWE1 suppresses protein and mRNA levels in 
HCC827 cells 
 To suppress HUWE1 expression in HCC827 cells, we cloned a shRNA 
targeting the coding sequence of HUWE1 mRNA into a doxycycline-inducible pLKO 
lentiviral vector.  After treating cells with doxycycline for 3 days to induce shRNA 
expression, we found a significant reduction in HUWE1 protein and mRNA levels (Figure 
10).  No significant changes were observed in control cells or in cells transduced with 
HUWE1 shRNA but not treated with doxycycline suggesting this system has minimal 
leakage and is suitable HUWE1 suppression.  To assess the specificity of primer pairs 
during qPCR analysis of mRNA levels of HUWE1 transcript, a melt-curve analysis was 
performed.  A single peak was observed (data not shown) at °C for control primer, and 













Figure 10.  shRNA targeting HUWE1 suppresses protein and mRNA expression. 
(A) Western blot for HUWE1 in HCC827 cells expressing inducible shHUWE1 or 
control shGFP.  shHUWE1 was induced by exposing cells to doxycycline (Dox)-





Suppression of HUWE1 in EGFR-mutant lung cancer cells decreases dependence 
on EGFR in HCC827 cells.   
To confirm if suppression of HUWE1 can modify dependence of mutant-EGFR 
signaling in response to erlotinib treatment, we constructed a shRNA targeting HUWE1 
or a control shRNA targeting GFP in doxycycline-inducible expression vectors.  We then 
infected HCC827 cells to generate stably transduced cell populations (TetOn-shHUWE1 
or TetOn-shGFP). Consistent with the results obtained by the sgRNA screen performed 
by the Cheung lab, inducible shRNA-mediated suppression of HUWE1 in HCC827 cells 
increased cell viability in the presence of erlotinib treatment compared to cells cultured in 
the absence of doxycycline or cells expressing a control shGFP (Figure 11).  
Phosphorylated EGFR remained inhibited in cells that retained viability (Figure 17), 
indicating that failure of erlotinib to inhibit EGFR signaling was not contributing to the 





Figure 11. Suppression of HUWE1 in HCC827 cells decreases sensitivity to 
erlotinib.  (A) CellTiter-Glo luminescence assay measuring viability of Dox-inducible 
shHUWE1 versus control in the presence of erlotinib for 3 days in concentrations 
ranging from 0-10 µM.  (B) Bar graph representing cell viability in the presence of 
erlotinib (0.1 µM).  Mean and standard deviation representative of 3 independent 
experiments.  (C)  Bar graph representing cell viability in the presence of erlotinib (1 






Suppression of HUWE1 increases tumor cell survival following exposure to EGFR-
TKI 
 To further investigate whether increased cell viability that was observed 
was due to avoidance of apoptotic cell death or increased cell proliferation, we 
performed Annexin V staining on HCC827-shHUWE1 cells treated with erlotinib for 24 
hours.  We found that cells with suppressed HUWE1 expression had a significantly 
smaller population undergoing early-stage apoptosis (Annexin V-positive, propidium 
iodide-negative) than control cells (Figure 12).  These results indicate that resistance 
was, at least in part, being mediated by decreased apoptosis and increased survival in 
HUWE1-suppressed cells.  
 
 
Figure 12. Suppression of HUWE1 in HCC827 cells attenuates apoptosis in 
response to EGFR-TKI.  (A)  FACS analysis of HCC827 cells stained with Annexin V 
and PI after erlotinib treatment for 24 hours.  (B)  Quantification of Annexin V-positive 




HUWE1 suppression does not promote increased tumor cell proliferation upon 
EGFR-TKI 
To investigate the effects of HUWE1 suppression on cell cycle, HCC827 cells 
were treated with erlotinib for 24 hours and stained with propidium iodide followed by 
FACS analysis.  To determine the proliferative ability, HUWE1-suppressed cells were 
analyzed by FACS for BrdU uptake, an indicator of DNA synthesis.  We found that 
suppression of HUWE1 did not affect cell cycle in response to erlotinib (Figure 13 A and 
B).  However, erlotinib retained a dramatic effect on S phase regardless of whether 
HUWE1 was suppressed.  We also found that HUWE1 suppression did not affect 
proliferative ability of the cells as there was no significant difference in BrdU uptake, a 
measure of DNA synthesis (Figure 13 C and D).  Taken together, these data suggest 
that suppression of HUWE1 confers an erlotinib-resistant phenotype that is not mediated 










Figure 13.  Suppression of HUWE1 in HCC827 cells does not affect cell cycle or 
proliferative ability in response to erlotinib.  (A)  FACS analysis of cell cycle 
populations in HCC827 cells after erlotinib treatment for 24 hours.  (B)  Quantification 
of cell populations (%).  Mean and standard deviation representative of three 
independent experiments.  (C)  FACS analysis of BrdU incorporation after erlotinib 
treatment for 24 hours.  (D)  Quantification of BrdU-positive cell population.  Mean and 





Suppression of HUWE1 in EGFR-mutant lung cancer cells promotes tumor cell 
survival upon EGFR inhibition through reactivation of AKT and ERK1/2 signaling  
To determine whether suppression of HUWE1 in HCC827 cells affected activities 
of AKT and ERK1/2 signaling upon erlotinib treatment, we cultured HCC827-TetOn-
shHUWE1 cells in the presence or absence of doxycycline for 4 days. Then we exposed 
them to different concentrations of erlotinib (0, 0.1, 1, and 10 μM) for 6 hours for 
immunoblot analyses. We found that phosphorylation of EGFR was similarly reduced in 
cells with or without HUWE1 suppression (Figure 14) after exposure to erlotinib. This 
result indicates that erlotinib was continuing to inhibit EGFR signaling in these cells, 
suggesting that drug resistance is occurring via an alternative mechanism. However, 
increased levels of phosphorylated-AKT (S473) and phosphorylated-ERK1/2 were 
detected in cells with HUWE1 (+Dox) suppression in response to erlotinib treatment 
compared to cells without HUWE1 suppression (-Dox) (Figure 14).  Taken together, 
these data suggest that suppression of HUWE1 reactivates AKT and ERK1/2 signaling 
to activate downstream survival pathways and, moreover, to partially relieve cells of their 





Figure 14. Suppression of HUWE1 in HCC827 cells reactivates AKT and ERK1/2 
signaling despite the presence of EGFR inhibition. (A) Western blot for HUWE1 in 
HCC827 cells expressing inducible shHUWE1 or control shGFP.  shHUWE1 was 
induced by exposing cells to doxycycline-containing media for 4 days then exposed to 
erlotinib for 6 hours in concentrations ranging from 0-10 µM.  ß-actin was used as a 






Inhibition of PI3K or MEK suppresses EGFR inhibitor resistance induced by 
HUWE1 loss 
To examine potential treatment strategies for EGFR inhibitor resistance induced 
by HUWE1 loss, we looked to restore EGFR inhibitor sensitivity by combination therapy 
with the PI3K inhibitor BEZ235 and the MEK inhibitor AZD6244.  The restoration of 
EGFR-TKI sensitivity would indicate AKT and ERK1/2 signaling contribute to EGFR 
independence in HUWE1-suppressed cells. EGFR-mutant NSCLC cells were treated 
with erlotinib alone, erlotinib plus BEZ235, or erlotinib plus BEZ235 and AZD6244 for 72 
hours. Relative viability was determined by measuring cellular ATP content.  Combining 
erlotinib treatment with BEZ235 and AZD6244 in HUWE1-suppressed cells showed the 
greatest effect on cell viability, reducing the viability to a similar level seen in cells with 
uninhibited HUWE1 expression (Figure 15).  These results suggest that increased AKT 






Figure 15. Inhibition of PI3K or MEK suppress HUWE1 loss-induced resistance to 
EGFR inhibitor. (A) CellTiter-Glo luminescence assay measuring proliferation of 
HCC827 cells expressing shHUWE1 in the presence of erlotinib alone, erlotinib and 
BEZ235, erlotinib and AZD6244, or erlotinib and BEZ235 and AZD 6244 versus non-
induced shHUWE1 cells. 
 
 
Suppression of HUWE1 increases ERK signaling in response to EGFR inhibition 
through stabilization of SHOC2  
Previous studies have identified numerous candidate substrates that are directly 
regulated by HUWE1, such as SHOC2, RAF1, MCL1, and c-MYC.   Therefore, we next 
investigated whether suppression of HUWE1 in HCC827 cells affected the levels of 
these substrates by immunoblot analyses. We found that suppression of HUWE1 led to 
increased protein levels of SHOC2 and c-Myc but did not affect the levels of RAF1 or 
MCL1 compared to cells with uninhibited HUWE1 expression (Figure 16).  Induction of 
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BH3-only pro-apoptotic protein, specifically BIM, is necessary for erlotinib-mediated 
apoptosis, so we therefore wanted to know whether suppression of HUWE1 attenuates 
BIM induction in response to erlotinib.  We found that suppression of HUWE1 led to 






Figure 16. Suppression of HUWE1 in HCC827 cells increases SHOC2 and c-MYC 
levels and decreases BIM levels (A) Western blot for HUWE1 in HCC827 cells 
expressing inducible shHUWE1 or control shGFP.  shHUWE1 was induced by 
exposing cells to doxycycline (Dox)-containing media for 4 days then exposed to 
erlotinib for 6 hours in concentrations ranging from 0-10 µM.  ß-actin was used as a 
loading control.  Densitometry quantification is relative to DMSO-treated in the 
absence of doxycycline. 
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Gene set enrichment analysis identifies differentially expressed transcripts in 
HUWE1-suppressed cells critical for EGFR-TKI response 
To identify key genes critical to EGFR-TKI response whose expression may be 
altered upon erlotinib treatment when HUWE1 is suppressed, we performed gene set 
enrichment analysis on preliminary transcriptional profiling data performed by Dr. 
Cheung’s laboratory.  As expected, we found enrichment of a gene set that is 
downregulated by EGFR-TKI in sensitive EGFR-mutant NSCLC cells (Figure 17).  This 
gene set was identified by the Kobayashi group when they used transcriptional profiling 
to determine genes whose down regulation is critical for EGFR-TKI sensitivity.  
Kobayashi et al., used H1975 cells which are EGFR-mutant but carry a T790M mutation 
rendering them insensitive to 1st generation EGFR-TKIs such as gefitinib due to 
ineffective drug binding.  These cells were treated with DMSO, gefitinib or the 
irreversible EGFR inhibitor EKI-785 to which the cells are sensitive.  Many of the genes 
highly down-regulated were factors regulated by EGFR signaling, those involved in a 
negative feedback loop of the MAPK pathway induced by oncogenic EGFR signaling, 
and activator protein-1 components such as c-Jun and FOS-like antigen1—mediators of 
MAPK and STAT signaling. 
Of the 242 genes in this gene set, 157 are contained in the leading edge—those 
that contribute most to the enrichment.  An enrichment heat map of these core genes 
are shown in Figure 18.  These data suggest that HUWE1 suppression confers EGFR-






Figure 17.  Kobayashi_EGFR_Signaling_24HR_DN Gene set enrichment analysis 
plot.  Genes in this set are downregulated after 24 hour treatment with EGFR-TKI in 
EGFR-TKI-sensitive NSCLC cells.  This plot represents enrichment of genes in 
HUWE1-suppressed HCC827 cells versus control cells using preliminary data obtained 





Figure 18.  Core enrichment genes in Kobayashi_EGFR-Signaling_24HR_DN gene 
set.  Enrichment heat map of core genes contributing to gene set enrichment.  Each 
column indicative of independent experiment replicates. 
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Discussion and alternative approaches 
 
 
In this aim, I showed that suppression of HUWE1 in NSCLC cells confers 
erlotinib resistance by reactivating ERK1/2 and AKT signaling pathways despite 
continued erlotinib exposure, allowing the cancer cells to escape apoptotic cell death.  
Combined inhibition of EGFR, ERK1/2 and AKT partially reversed resistance in HUWE1-
suppressed cells and reduced cell viability to levels similar to control cells.  This 
suggests that increased AKT and ERK1/2 signaling mediates the observed EGFR 
independence induced by HUWE1 suppression.  
 Cells with suppressed HUWE1 expression in the presence of erlotinib had 
higher viability compared to control cells and had significantly fewer cells in early 
apoptosis as determined by FACS analysis.  There were no observed changes in cell 
cycle when HUWE1 was suppressed in response to erlotinib treatment, suggesting that 
reactivation of ERK1/2 and AKT mediated by HUWE1 suppression confers EGFR-TKI 
resistance by allowing tumor cells to escape erlotinib-induced apoptotic cell death.   
Further investigation into how loss of HUWE1 mediates reactivation of ERK1/2 
and AKT are warranted.  One possible explanation is an increase in SHOC2 expression 
observed in shHUWE1-expressing cells.  A known substrate of HUWE1, SHOC2, has 
been thought to accelerate the association of the RAS-RAF1 complex to regulate the 
ERK1/2 pathway [137]. 
We showed that after treatment with erlotinib, BIM induction was attenuated in 
HUWE1-suppressed cells compared to cells with uninhibited HUWE1 expression.  
Additional experiments should be performed to verify these results as well as to 
determine at what level BIM is regulated.  For example, phosphorylation of BIM through 
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activation of ERK1/2 is sufficient for degradation of BIMEL. However, BIM regulation may 
be mediated by other downstream kinases such as RSK1 [138], which is involved in cell 
survival.  
We also showed that when HUWE1 is suppressed in HCC827 cells, there is an 
enrichment of expression of genes normally downregulated in response to EGFR-TKI in 
EGFR-mutant NSCLC.  While we found a relatively large number of core differentially 
expressed genes enriched in response to erlotinib in HUWE1-suppressed cells that are 
down-regulated in sensitive cells, Cyclin D1 is particularly interesting.  Cyclin D1 is a 
target of EGFR signaling whose expression is repressed upon erlotinib treatment in 
sensitive cells, and its down-regulation has been correlated with sensitivity to EGFR-
TKIs [139].  Deletion of HUWE1 has been shown to repress MYC/MIZ1-mediated 
transcription of cyclin-dependent kinase inhibitor 2b [132], suggesting a possible 
mechanism of cyclin D1 enrichment. 
For the experiments we performed, determination of cell viability relied on 
luminescent detection of ATP, an indicator of metabolic activity.  While the experiments 
we performed were confirmed by triplicate experiments, there are several caveats worth 
mentioning when observing phenotypes by use of this assay.  First, clear bottom plates 
were used, which makes for easier microscopic monitoring of cells through the duration 
of the experiment. However, it is possible to have increased signal crosstalk between 
wells.  Additionally, if cells are plated at high density, contact growth inhibition may 
decrease cellular ATP, resulting in a non-linear relationship between luminescence value 
and cell number. 
Advancements in CRISPR-mediated gene suppression employ a “nickase” Cas9 
variant that generates a single- rather than a double-strand break to which the sgRNA 
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binds.  By using paired sgRNAs to induce a double-strand break (one complementary to 
the sense strand and one complementary to the antisense strand), the probability of off-
target binding within proximity to induce double-strand-break repair is low, thus reducing 
the off-target effects.  Yet another CRISPR system seeks to further reduce off-target 
repair by fusing a Fok1 nuclease domain to a catalytically inactive Cas9.  Again, double-
strand breaks are achieved using paired sgRNAs.  However, unlike Cas9, Fok1 must 
dimerize to generate a double-strand break [140].  Employing these CRISPR systems 
















Specific Aim #2:  Assess the effects of HUWE1 suppression on tumor growth and 
survival in vivo.  A human xenograft mouse model was established to determine if 
suppression of HUWE1 affects tumor growth and survival in an in vivo setting.  
Validation of the sgRNA screen results in vitro indicated that HUWE1 can relieve EGFR-
mutant NSCLC cells from their dependence on oncogenic EGFR signaling.  Thus, the 
validation in vivo will support further studies of loss-of-HUWE1 as an EGFR-TKI 
resistance mechanism that may have clinical relevance. 
Task #1:  Establish HCC827-shHUWE1 xenografts in athymic nude mice and 
assess effects of HUWE1 suppression on tumor growth in response to erlotinib. 
Task #2:  Perform immunohistochemistry on tumor sections to visualize protein 
levels of p-AKT, p-ERK1/2, Ki67, and cleaved caspase-3. 
Experimental Design 
Cell culture:  HCC827 cells were cultured in RPMI medium (Corning) 
supplemented with 10% fetal bovine serum (FBS; Corning) and 1× Penicillin-
Streptomycin (Corning). Tetracycline-free FBS (Clontech) was used when tetracycline 
inducible expression system (TetOn) was applied. Packaging cells (293T) were cultured 
in DMEM medium (Corning) supplemented with 10% FBS (Corning). 
Chemicals:  Erlotinib was purchased from Selleck Chemicals and resuspended 
in 0.5% methylcellulose solution (Sigma).  
Assessment of in vivo tumor growth in response to EGFR-TKI by 
xenograft:  HCC827 cells stably transduced with pLKO-TetOn-shGFP or pLKO-TetOn-
shHUWE1 were cultured as previously described.  Cells were trypsinized, washed twice 
in 1× PBS, and resuspended in 1× PBS.  In a volume of 200 µL of 1× PBS, 5×106 cells 
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were implanted subcutaneously into the left and right flanks of male athymic nude mice 
(Harlan Laboratories). Tumors were allowed to grow for 13 days before feeding mice 
with a normal diet or a doxycycline-containing diet (Harlan Laboratories). Starting from 
17 days post implantation, tumor-bearing mice were either treated with erlotinib (25 
mg/kg) once daily by oral garage or untreated. The size of tumors was measured by a 
digital caliper every 2 days.  
   Tumor volume = (width)2 × length/2. 
 All tumors were fixed in 10% neutral buffered formalin for Hematoxylin and Eosin 
(H&E) staining and immunohistochemistry. 
Immunohistochemistry:  Formalin-fixed xenograft tumors were paraffin-
embedded and sectioned (5 μm thick) by the Biorepository at the Medical University of 
South Carolina.  Sectioned slides were prepared for immunohistochemistry by placing 
them in xylene 3 times for 5 minutes each time, 100% ethanol twice for 3 minutes each 
time, 95% ethanol once for 2 minutes, 80% ethanol once for 2 minutes, and 70% ethanol 
once for 5 minutes, followed by PBS for 5 minutes.  Antigen retrieval was performed 
using the sodium citrate method by placing the slides into boiling sodium citrate (10 mM, 
pH 6) and microwaving them for 20 minutes at power level 5 (1200 watts). Endogenous 
peroxidase activity was blocked by incubating slides with 0.3% hydrogen peroxide 
(Sigma) in 1× PBS for 10 minutes and rinsed with distilled water (3 times for 5 minutes 
each) and PBS (once for 5 minutes).   
To reduce background signal, sections were incubated with 2.5% goat serum 
blocking solution (Vector Labs) for 30 minutes.  Blocking solution was removed and 
primary antibodies were immediately applied as follows:  Cytokeratin 7 (1:100, Abcam); 
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Ki67 (1:100, Vector Labs); p-AKT Ser473 (1:100, Cell Signaling), p-ERK1/2 
Thr202/Tyr204 (1:400, Cell Signaling) Cleaved caspase-3 (1:300, Cell Signaling).  Slides 
were incubated overnight at 4°C.  Slides were rinsed 3 times for 5 minutes each rinse in 
preparation for secondary antibody application.  Biotinylated goat anti-rabbit or anti-
mouse secondary antibodies were diluted (1:500) in 2.5% goat blocking serum in PBS.  
Appropriate secondary antibodies were added to slides and incubated for 1.5 hours.  
Primary antibodies were detected by using VECTASTAIN Elite ABC kit and DAB 
Peroxidase substrate kit (Vector Labs).   
In preparation of primary antibody detection, slides were washed 3 times for 5 
minutes each with PBS.  ABC reagent was mixed according to manufacturer’s 
instructions, applied to tissue sections, and incubated for 30 minutes.  Slides were 
washed 3 times for 5 minutes each time with PBS.  DAB reagent was prepared 
according to manufacturer’s instructions and immediately applied to tissue sections after 
removal of ABC reagent.  DAB reagent was incubated with slides until maximum color 
saturation was observed (2-10 minutes).  Slides were then rinsed in distilled water for 5 
minutes.  Slides were counter-stained with hematoxylin (Vector Labs) for 1 minute and 
45 seconds and rinsed with distilled water (2 times for 10 minutes each).  Sections were 
dehydrated prior to applying coverslip by incubating in 75% ethanol for 5 minutes 
followed by 95% ethanol for 10 minutes, 100% ethanol for 10 minutes, and xylene (2 







To examine the effects HUWE1 suppression on tumor growth upon erlotinib 
treatment in vivo, we used a doxycycline- inducible shRNA xenograft model in athymic 
nude mice.  Mice were randomized and placed in 4 treatment groups: 1) No Dox, No 
erlotinib; 2) No Dox, Plus erlotinib; 3) Plus Dox, No erlotinib; and 4) Plus Dox, Plus 
erlotinib. HCC827 cells stably expressing inducible shHUWE1 were injected into the left 
and right flanks of the mice, and tumor development was monitored every other day by 
bilateral caliper measurement until average tumor diameter reached 10 mm. At that time, 
the tumors were excised, fixed, paraffin-embedded and sectioned.  For the “Plus Dox” 
treatment groups, a doxycycline-containing diet was started 13 days after injection and 
continued for the duration of the experiment.  Beginning 17 days after injection, erlotinib 
dosing was administered daily at 25 mg/kg by oral gavage, allowing time for induction of 
shHUWE1 expression after starting mice on doxycycline-containing diet (Figure 19). 
 
 
Figure 19. Timeline of xenograft experiment.  HCC827 cells expressing inducible 
shHUWE1 implanted subcutaneously into the left and right flanks of athymic nude 
mice.  After allowing tumors to grow for 13 days, mice were fed either normal or 
doxycycline-containing diet for the duration of the experiment.  Erlotinib (25 mg/kg) 
was administered daily by oral gavage beginning on day 17 to allow for shHUWE1 to 
be induced.  Upon initiation of erlotinib treatment, tumor volume was measured every 
other day using digital calipers.  Mice were sacrificed when tumor size reached 1 cm in 







We found that erlotinib treatment of mice that were fed with normal diet (-Dox) 
led to durable tumor regression throughout the treatment period. In contrast, mice fed 
with doxycycline-containing diet (+Dox) tumors regressed initially upon erlotinib 
treatment but continued to grow into large tumors (n=5, P<0.0001) (Figure 20 A). The 
tumors were excised at the end of the experiment and we found that the average of 
erlotinib-treated tumors with HUWE1 suppression were significantly heavier by weight 
than those with uninhibited HUWE1 expression (P<0.0001) (Figure 20 B).  Taken 
together, these results show that suppression of HUWE1 in EGFR-mutant lung cancer 





Figure 20. Suppression of HUWE1 increases tumor volume and weight after 
erlotinib treatment. (A) Tumor volume of murine xenografts (N=5) of subcutaneously 
implanted HCC827 cells expressing inducible shHUWE1.  A doxycycline diet was 
administered 4 d prior to erlotinib treatment.  Erlotinib was administered daily by oral 
gavage at a dosage of 25 mg/kg.  (B)  Scatter plot of tumor weight after excision.  
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To examine the effects HUWE1 suppression on AKT and ERK1/2 signaling in 
vivo, we performed immunohistochemistry on the tumor sections, staining for 
phosphorylated-AKT as well as phosphorylated-ERK1/2.  In erlotinib-treated cells with 
HUWE1 suppression, we observed increased staining across both markers (Figure 21).  
This indicates HUWE1-suppression resulted in increased AKT and ERK1/2 signaling 
and suggests that the reactivation of these survival pathways contributed to the resistant 
phenotype.  We also observed minimal differences in the untreated groups, confirming 












Figure 21. Suppression of HUWE1 in HCC827 xenografts reactivates AKT and 
ERK1/2 signaling in the presence of EGFR-TKI.  Immunohistochemistry for p-AKT 
and p-ERK1/2 on tumors expressing Dox-inducible shHUWE1 implanted 
subcutaneously on left and right flanks of male athymic nude mice.  After 13 days, 
mice were fed a Dox-containing diet for 3 days prior to erlotinib treatment.  Mice were 






Suppression of HUWE1 promotes EGFR-independent tumor growth by enhancing 
tumor cell proliferation and survival 
To investigate the mechanisms by which suppression of HUWE1 promoted tumor 
growth upon erlotinib treatment, we performed immunohistochemistry on xenograft 
sections using antibodies against Ki67 and cleaved caspase-3 to analyze tumor cell 
proliferation and apoptosis, respectively. Staining for cytokeratin 7 was also performed to 
assist in identification of epithelial tumor cells. We found that erlotinib-treated tumors 
with uninhibited HUWE1 expression (-Dox, +Erlotinib) dramatically inhibited tumor cell 
proliferation and increased apoptotic cell death, whereas a relatively higher number of 
proliferating cells and lower number of apoptotic cells were detected in tumors in which 
HUWE1 was suppressed (+Dox, +Erlotinib) (Figure 22).  These results suggest that 
suppression of HUWE1 promotes EGFR-independent tumor growth by enhancing tumor 





Figure 22. Suppression of HUWE1 in HCC827 xenografts increases proliferation 
and survival in response to EGFR-TKI.  Immunohistochemistry for cytokeratin 7 and 
cleaved caspase-3 on tumors expressing Dox-inducible shHUWE1 implanted 
subcutaneously on left and right flanks of male athymic nude mice.  After 13 days, 
mice were fed a Dox-containing diet for 3 days prior to erlotinib treatment.  Mice were 
administered 25 mg/kg of erlotinib daily for 39 days. 
 
Discussion and alternative approaches:  
In this aim, I showed that suppression of HUWE1 in a human tumor xenograft 
model decreased the dependence on oncogenic EGFR signaling in EGFR-mutant lung 
cancer cells for tumor growth in response to erlotinib treatment.  
Consistent with our in vitro results, we found by immunohistochemistry staining 
higher levels of phosphorylated-ERK1/2 and phosphorylated-AKT suggesting that these 
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signaling pathways may be involved in the increased tumor growth found in HUWE1-
suppressed cells.  Cleaved caspase-3 staining revealed that increased tumor growth is 
at least partially attributed to a decrease in tumor cells entering apoptosis upon erlotinib 
treatment.  Interestingly, our in vivo data suggests that there is an increase in 
proliferation in these cells as well contrary to our in vivo data.  One possible explanation 
is non-specific Ki67 staining, but further investigation is needed. 
There are many variables that must be considered when conducting xenograft 
experiments.  Site of implantation, agent formulation, dosing schedule, route of 
administration, and determination of experiment endpoint can all significantly affect 
outcome.  Xenografts derived from cell lines undergo extensive selective pressures in 
culturing that may result in a more homogenous population than typically observed in 
patients.  However, this relative homogeneity can be overcome by using xenografts 
derived directly from patient biopsies.  Additionally, the surrounding tumor 
microenvironment—consisting of mainly fibroblasts, endothelial cells, and circulating 
immune cells—can impose selective conditions that greatly influence tumor growth and 
survival [141].  Thus, drug responses in xenograft models do not often correlate with 
patient responses in the clinic [142].  Despite this limitation, the results should not be 
discounted.  Preclinical data obtained from human tumor xenografts have led to 
successful clinical trials.  For example, HER2/neu-overexpressing human breast cancer 
xenografts led to the subsequent success of Herceptin combined with paclitaxel and 
doxorubicin to enhance anti-tumor activity in the clinic [143].   
An alternative approach to overcome the limitations of the murine 
microenvironment is to partially reconstitute the human immune system to more 
accurately reflect the tumor microenvironment seen in human disease.  Mice can be 
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“humanized” by direct injection of human peripheral blood [144] or implantation of human 
stromal tissue together with the tumor tissue [145].  Employing a humanized mouse 
model is expensive and technically challenging, and it should be noted that while 
humanized mice may help bridge the gap between human tumor tissue and the 
surrounding microenvironment, full restoration of HLA class I- and class II- selecting 
elements in T-cell populations remains a challenge [146]. 
 
Future Experiments 
Validation of HUWE1 in additional cell lines and additional HUWE1-targeted 
shRNA 
 To improve our confidence that HUWE1 is a true modifier of EGFR 
dependence in EGFR-mutant NSCLC, I believe it is necessary to include additional cell 
lines in xenograft studies and determine whether the resistant phenotype is observed.  
To strengthen our observations further, additional shRNAs targeting HUWE1 should be 
employed. 
Confirming the specificity of HUWE1-targeting shRNA 
 A caveat of shRNA-mediated gene suppression is the possibility that the 
observed phenotype is the result of off-target effects.  Off-target effects can generally 
arise through complementarity of the shRNA sequence to unintended transcripts as well 
as saturation of the endogenous processing machinery, resulting in altered miRNA 
expression that could affect the observed phenotype.  Well-designed shRNA sequences 
can mitigate off-target effects, but a critical step to show that direct HUWE1 suppression 
is mediating the observed phenotype is to ectopically express HUWE1 cDNA to rescue 
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the resistant phenotype.  One method is to express cDNA of HUWE1 that contains a 
silent mutation in the region complementary to the shRNA target.  By attaching an 
epitope tag, one can determine silencing of the endogenous protein but not the ectopic 
expression, as the epitope tag will cause a shift that can be identified by electrophoresis.  
An alternative approach would be to target the 3’ untranslated region not present in the 
cDNA expression vector. 
 In the case of HUWE1, ectopic expression provides a specific challenge in 
that the open reading frame for HUWE1 is approximately 13kb, which can significantly 
limit lentiviral delivery due to low titers.  Direct ordering of lentiviral particles is available, 
but due to the excessive cost, resource allocation needs to be considered.  An 
alternative approach is to utilize the CRISPR/Cas9 system for gene activation.  By fusing 
a catalytically inactive Cas9 fused to a transcriptional activator, we can target the 
HUWE1 promoter to activate gene transcription [147].  While shHUWE1 will target this 
transcript as well the increased expression may outcompete the ability of the shRNA-
mediated suppression.  This method of HUWE1 overexpression also has the added 
benefit of expression being driven by the endogenous promoter. 
Targeting of additional bypass signaling tracks 
Alternative kinase inhibitors targeting secondary EGFR mutations such as 
T790M are ineffective in the treatment of resistance mediated by the activation of 
parallel signaling pathways.  A combination therapeutic approach is necessary in this 
setting.  While this study focused on combined inhibition of EGFR with PI3K and MEK, 
other signaling pathways should be explored.  STAT3 has been shown to be induced in 
response to erlotinib in EGFR-mutant NSCLC cell lines and associated with drug 
resistance [148, 149].  Niclosamide, an inhibitor of STAT3, has been shown to reverse 
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resistance in pooled populations of erlotinib-resistant populations of HCC827 cells [150].  
Additionally, erlotinib and niclosamide work synergistically in the treatment of head and 
neck cancer [151].  While there may not be a direct relationship between HUWE1 and 
STAT3 signaling, the fate of cell survival is often a balance between pro- and anti-
apoptotic signaling, and inhibition of erlotinib-mediated STAT3 induction in HUWE1-
suppressed tumors may shift the balance to induce apoptosis and reverse resistance. 
Clonogenic survival assay 
 To further characterize HUWE1-mediated cell death in response to EGFR-
TKIs, clonogenic survival assays can determine the ability of a cell to retain its 
reproductive ability to form a large colony or clone.  Removing the drug after an 
empirically determined time period has the added benefit of determining if the drug effect 
is irreversible. 
HUWE1 substrate identification 
 While we have shown that suppression of HUWE1 reactivates AKT and 
ERK1/2 signaling to mediate EGFR-TKI resistance, little is known about how HUWE1 
interacts with intermediate effectors involved to accomplish signal transduction.  The 
identification of substrates targeted by HUWE1 in the context of EGFR inhibition is 
challenged by the often weak or transient interactions between E3 ligases and their 
substrates, making identification by immunoprecipitation and mass spectrometry difficult 
[152].  Ubiquitinated proteins may be rapidly degraded by the proteasome, and the use 
of proteasome inhibitors can have other biological consequences [153].   An emerging 
strategy to identify E3 ligase substrates is proximity-dependent biotin labeling in which 
an E3 protein is fused with a biotin-conjugating enzyme which reacts with nearby amine 
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groups on lysine residues.  Interacting proteins can then be identified with semi-
quantitative mass-spectrometry [154]. 
Analysis of patient tumor samples 
The gold standard for tumor drug resistance studies is confirming candidate 
resistance effectors are relevant to cancer patients.  Patient-matched tumor tissue 
obtained before treatment, and after tumor progression, should be analyzed for 
mechanistic characterization.  Post-progression re-biopsies are often difficult to obtain 
due to the invasiveness of the procedure, and thus, acquiring a specimen collection that 
can provide significant insight presents a challenge. 
Analysis of additional genes identified by CRISPR screen 
The validity of the CRISPR/Cas9 knockout screen performed by the lab of Dr. 
Cheung was demonstrated by the identification of genes known to mediate EGFR-TKI 
resistance such as PTEN, NF1, NF2, TSC1, TSC2, and MED12.  Furthermore, HUWE1, 
which has previously no known role in modifying EGFR dependence in EGFR-mutant 
NSCLC, was also validated by this study.  This validity warrants further investigation of 
other novel genes identified by their screen, which could provide insights as to how 
these cells escape EGFR dependence upon EGFR inhibition.  One such gene is inhibitor 
of kappa B-zeta (IκBζ), which has been shown to regulate NF-κB and STAT3 signaling 
[155, 156], both of which have been implicated in EGFR-TKI resistance [53, 148]. 
I believe this study provides the foundation to support HUWE1 as a modifier of 
EGFR dependence in EGFR-mutant NSCLC. However, numerous questions remain 
unanswered, and thus, further investigation is warranted.  I believe the additional 
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aforementioned methods can provide mechanistic insight that could have clinical 
relevance. 
 
Significance of study 
Activating EGFR mutations in NSCLC have proven to be the Achilles’ heel of 
these tumors, paving the way for the clinical success of EGFR-TKI inhibitors.  
Unfortunately, all patients who initially respond to this therapy will develop acquired 
resistance, demonstrating the persistent need to understand the underlying mechanisms 
involved.  This need for understanding is truer now that we have seen several resistance 
mechanisms existing in patients synchronously or concurrently.  To successfully 
overcome acquired EGFR-TKI resistance, combinational regimens will need to be 
explored.  Overcoming acquired EGFR-TKI resistance requires the identification of 
genes that have the ability to allow tumor cells to escape their dependence on oncogenic 
EGFR signaling. 
This study provides the first evidence showing that suppression of HUWE1 in 
EGFR-mutant lung cancer cells decreases dependence on EGFR signaling in response 
to EGFR inhibition.  The underlying mechanisms involve the activation of both AKT and 
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